Duravest, Inc.
OTC Bulletin Board : DUVT

Duravest, Inc.

January 17, 2006 11:22 ET

Duravest, Inc. Announces Corporate Vision and Initial Appointments to its Medical Advisory Board

CHICAGO--(CCNMatthews - Jan 17, 2006) -

Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) is a publicly traded holding company that initiates strategic investments in leading edge medical technologies. Its subsidiary, Estracure, Inc. is currently developing a next-generation coronary stent based on proprietary estrogen-based technologies which may minimize restenosis and potentially prevent progression of coronary lesions. Based on the results of a multi-center Phase II "proof-of-concept" trial in humans and ongoing pig trials, Phase II/III trials with the proprietary 17-beta-estradiol, stent and polymer combination are being currently planned for patient accrual later this year. Duravest also has a controlling interest in Bio-Magnetic Therapy Systems, Inc. (BMTS), a leading German-US medical technology firm dedicated to the safe, non-invasive treatment of osteoarthritis, osteoporosis and orthopedic injuries. Its proprietary, patented devices are already used clinically in Germany while further expansion is planned for European, Asian and U.S. markets.

The strategic vision for Duravest encompasses three themes: (1) providing its subsidiaries with financial and operational support to rapidly commercialize the next-generation medical technologies in its portfolio, (2) prioritization of safety, and (3) a focus on the development of cross-technologies that span traditional categories of biotechnology, pharmaceuticals, healthcare IT and medical devices. "The future of healthcare lies in areas such as drug-device combos, nanotechnology, "theranostics" and smart devices which require a deep understanding of interdisciplinary technologies" -- according to Dr. Ogan Gurel, Duravest's Chief Executive Officer. To assist its subsidiaries and develop its unique expertise in cross-disciplinary technology development, Duravest has assembled world-class medical advisory board (MAB) and scientific advisory boards (SAB). The company is pleased to announce two initial appointments -- Ron Waksman, MD and Peter Bonis, MD to its medical advisory board.

Dr. Waksman graduated from the Ben Gurion University in Israel. He completed residency training in medicine and cardiology at Hadassah University in Jerusalem and at Emory University Hospital in Atlanta. He is currently Associate Director of the Division of Cardiology at Washington Hospital Center in Washington, DC and Director of Experimental Angioplasty and new techniques for the Cardiovascular Research Institute at the Washington Hospital Center. He holds an academic appointment as Clinical Professor of Medicine (cardiology) at Georgetown University School of Medicine. Dr. Waksman has conducted extensive pre-clinical and clinical research involving advanced techniques in angioplasty (including drug-eluting stents) and has been a consultant to numerous companies involved in all aspects of this field. He is a member of the American College of Cardiology and the Society for Cardio Angiography and Interventions as well as an active faculty member at the annual Transcatheter Cardiovascular Therapeutics (TCT) conferences. A world-leading expert in the field of interventional technology, he is an editor of three books and has authored more than 250 peer reviewed articles in the medical literature. Dr. Gurel noted that "Dr. Waksman's deep expertise in advanced interventional cardiology technologies as well as with the design and implementation of clinical trials -- especially with an emphasis on the thorough evaluation of safety -- will be of tremendous value for our Estracure subsidiary. In addition, Dr. Waksman's strength in integrating advanced physics with leading-edge clinical technology will also help to advance our core Duravest mission of rapidly bringing to market safe, cross-disciplinary medical technologies." Dr. Waksman commented that, "I am pleased at the prospect of working with Dr. Gurel and with the other members of the Duravest Medical Advisory Board."

Dr. Bonis graduated from Harvard College and New York University School of Medicine and completed post-graduate training in gastroenterology and health services research at the New England Medical Center, Tufts University School of Medicine. He is Director of Research and Deputy Editor of Gastroenterology and a member of the senior management team at UpToDate, a leading content provider of state-of-the-art clinical knowledge systems for clinicians. Dr. Bonis is Assistant Professor of Medicine at Tufts University School of Medicine and Assistant Director of the Tufts New England Medical Center Evidence Based Practice Center, a research affiliate of the Agency for Healthcare Research and Quality (AHRQ). He is an internationally recognized authority on clinical trial design, systematic reviews, meta-analysis and technology assessment and publishes regularly in major biomedical journals. He is an expert on communicating scientific knowledge to clinicians and in the processes by which physicians adopt new knowledge and technologies into clinical practice. Dr. Ogan Gurel, CEO of Duravest, Inc., remarked that "Dr. Bonis' outstanding credentials, diverse background and specific expertise at the highest levels of clinical trial design, outcomes research and physician adoption dynamics represent a truly unique and powerful resource for both Duravest and its subsidiaries. We are absolutely delighted with the appointment of Dr. Bonis to our world-class medical advisory board." According to Dr. Bonis, "I am delighted to join the medical advisory board in light of Duravest's vision and dedication toward rapidly bringing safe and innovative technologies to the marketplace. The major lapses recently seen in the safety of drugs and medical devices have stunned the medical community. Patients and caregivers are increasingly placing a large premium on safety, and Duravest is well-positioned to meet this important trend."

Additional appointments to the Duravest medical advisory board and scientific advisory board will be announced in the near future.

Background on Duravest, Inc.

Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) seeks innovative and safe medical technologies in their preclinical and breakthrough stages and helps move them toward successful commercialization through key strategic partnerships. Duravest is building the future of medicine now to create shareholder value and improve health.

Safe Harbor Forward Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.

Contact Information